Cancer Research

Is Luvelta the Next Breakthrough Drug for Treating NSCLC?
Research & Development Is Luvelta the Next Breakthrough Drug for Treating NSCLC?

Sutro Biopharma has announced a significant step forward in the fight against lung cancer by initiating a global Phase 2 clinical trial, aptly named REFRαME-L1, for their innovative drug luveltamab tazevibulin (luvelta). This trial aims to evaluate the safety and efficacy of luvelta in adults with

Will BNT326/YL202 Overcome Safety Issues to Become a Cancer Therapy?
Research & Development Will BNT326/YL202 Overcome Safety Issues to Become a Cancer Therapy?

The journey of developing groundbreaking cancer therapies is fraught with challenges and triumphs, and the clinical trial of BNT326/YL202 by BioNTech and MediLink Therapeutics is no exception. This antibody-drug conjugate (ADC) candidate has shown promise in treating non-small cell lung cancer and

FDA Lifts Hold on BioNTech and MediLink’s Cancer Drug Trial
Research & Development FDA Lifts Hold on BioNTech and MediLink’s Cancer Drug Trial

In an impressive turn of events, the U.S. Food and Drug Administration (FDA) has lifted the partial hold on BioNTech and MediLink Therapeutics' clinical trial for their groundbreaking Antibody-Drug Conjugate (ADC) candidate BNT326/YL202. Originally put on hold due to serious safety concerns, the

FDA Approves Tanvex's NYPOZI and Accepts BLA for Cancer Treatment
Research & Development FDA Approves Tanvex's NYPOZI and Accepts BLA for Cancer Treatment

In a significant breakthrough for cancer treatment options, Tanvex BioPharma USA, Inc. ("Tanvex" or the "Company") announced that the FDA has approved their biosimilar product NYPOZI (filgrastim-txid) and accepted their Biologics License Application (BLA) for TX-05. These milestones highlight

Accenture Invests in Earli Inc. for Breakthrough Cancer Detection Technology
Research & Development Accenture Invests in Earli Inc. for Breakthrough Cancer Detection Technology

Accenture, a global professional services company renowned for its expertise in strategy, consulting, and technology, has made a strategic investment in Earli Inc., a biotechnology firm dedicated to revolutionary early cancer detection. This strategic move is managed through Accenture Ventures and

SK Biopharma Secures $571.5M Deal with Full-Life for Cancer Drug FL-091
Research & Development SK Biopharma Secures $571.5M Deal with Full-Life for Cancer Drug FL-091

The recent $571.5 million licensing agreement between SK Biopharmaceuticals Co., Ltd., and Full-Life Technologies Limited marks a significant milestone in the biotech industry. This exclusive deal grants SK Biopharmaceuticals the rights to develop, manufacture, and commercialize FL-091, an

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later